Early Detection of Heart Failure in Hypertensive Patients

1. Introduction: Hypertension as the Leading Modifiable Risk Factor for Heart Failure

Hypertension precedes the majority of incident heart failure cases and remains the single largest modifiable contributor to population-level heart failure risk. Long-term cohort data indicate that most patients who go on to develop heart failure had documented hypertension years, often decades, beforehand - typically without overt cardiac symptoms in the intervening period.

This latency is clinically significant. The transition from hypertension to hypertensive heart disease, and from there to symptomatic heart failure, unfolds through a largely silent structural and functional remodelling process. By the time breathlessness, fatigue, or fluid retention prompt clinical presentation, meaningful myocardial remodelling has typically already occurred.

For clinicians managing hypertensive patients - particularly those with long-standing or historically poorly controlled disease, echocardiographic evidence of left ventricular hypertrophy, or coexisting risk factors such as diabetes or coronary disease - proactive surveillance for early markers of cardiac involvement represents a meaningful opportunity to intervene before the transition to overt heart failure.

This article outlines the mechanistic pathway from hypertension to heart failure, reviews the evidence supporting early detection strategies, and provides practical guidance on surveillance and preventive management.

2. Mechanisms: From Hypertension to Hypertensive Heart Disease

Sustained elevated afterload drives a sequence of structural and functional cardiac changes that, left unaddressed, progress toward clinical heart failure through two broadly distinct phenotypic pathways.

Left Ventricular Hypertrophy and Diastolic Dysfunction

Chronic pressure overload induces concentric left ventricular hypertrophy (LVH) as the myocardium adapts to sustained afterload. While initially compensatory, LVH is accompanied by impaired ventricular relaxation and increased chamber stiffness, producing diastolic dysfunction - the dominant early functional abnormality in hypertensive heart disease and the physiological substrate for heart failure with preserved ejection fraction (HFpEF).

Myocardial Fibrosis and Microvascular Dysfunction

Alongside myocyte hypertrophy, sustained hypertension promotes interstitial and perivascular fibrosis, driven partly by RAAS activation and chronic low-grade inflammation. Fibrotic remodelling further impairs diastolic compliance and is increasingly recognised as a contributor to coronary microvascular dysfunction, which is itself implicated in the pathophysiology of HFpEF independent of epicardial coronary disease.

Divergent Pathways to HFpEF and HFrEF

Most hypertensive patients who develop heart failure progress toward the HFpEF phenotype via the LVH-diastolic dysfunction pathway described above. However, a subset progress toward heart failure with reduced ejection fraction (HFrEF), typically where hypertension coexists with an additional insult - most commonly myocardial infarction, but also including longstanding uncontrolled hypertension causing eventual systolic decompensation. Recognising which trajectory is more likely in an individual patient informs the intensity and type of surveillance warranted.

3. Evidence Overview: Predicting Heart Failure Risk in Hypertensive Patients

A substantial evidence base now supports both the scale of hypertension-attributable heart failure risk and the value of structured early detection strategies.

Cohort Evidence on Progression

Longitudinal analyses from the Framingham Heart Study have shown that hypertension precedes the diagnosis of heart failure in the large majority of cases, with the population-attributable risk exceeding that of any other single modifiable risk factor. Separate Framingham analyses have demonstrated that echocardiographically determined LVH independently predicts subsequent cardiovascular events, including heart failure, providing a structural early marker that precedes symptom onset by years.

Natriuretic Peptide Screening Evidence

The STOP-HF trial demonstrated that natriuretic peptide-based screening (BNP) combined with collaborative cardiovascular care in patients with risk factors, including hypertension, significantly reduced the incidence of newly diagnosed left ventricular dysfunction and heart failure compared with usual care. This trial provides direct evidence that a structured, biomarker-led screening pathway in at-risk but asymptomatic patients can alter the trajectory toward overt heart failure, rather than merely detecting it earlier.

Guideline Positions

The 2021 ESC Heart Failure guidelines, updated in 2023, explicitly recognise hypertension as a Stage A risk factor for heart failure and support natriuretic peptide testing as a reasonable strategy for identifying at-risk patients who would benefit from closer surveillance or echocardiographic evaluation. The 2022 ACC/AHA/HFSA heart failure guideline similarly formalises the Stage A (at risk) and Stage B (pre-heart failure, structural disease without symptoms) categories, both of which are directly applicable to hypertensive patients before symptom onset, and both guidelines support blood pressure control as a cornerstone of prevention at every stage.

4. Clinical Assessment: Early Detection Strategies

Detecting hypertensive heart disease before symptomatic heart failure develops requires moving beyond reliance on symptom reporting, which characteristically emerges late in the disease process.

Clinical Red Flags

Even in the absence of classic heart failure symptoms, reduced exercise tolerance disproportionate to age and comorbidity, new or worsening peripheral oedema, unexplained weight gain, or a new third heart sound on examination warrant further evaluation in a hypertensive patient.

Natriuretic Peptide Testing

BNP or NT-proBNP testing offers a practical, accessible tool for risk-stratifying asymptomatic hypertensive patients, particularly those with additional risk factors. Elevated levels in this context should prompt echocardiographic evaluation rather than being interpreted in isolation, given the influence of age, renal function, and body habitus on natriuretic peptide levels.

Echocardiographic Assessment

Echocardiography remains the primary tool for detecting structural hypertensive heart disease, assessing left ventricular mass and geometry, diastolic function parameters, and left atrial size - the latter serving as a useful integrator of chronic diastolic pressure burden. Periodic echocardiographic reassessment is reasonable in patients with confirmed LVH or historically poorly controlled hypertension, at an interval guided by overall risk.

Longitudinal Home BP Patterns

Beyond a single mean BP value, longitudinal home BP data can surface patterns relevant to emerging cardiac involvement - including rising trends despite stable therapy, increasing pulse pressure, or reduced tolerance of previously well-tolerated antihypertensive doses - that may not be apparent from infrequent clinic visits alone and can prompt earlier clinical review.

5. Management Strategies: Preventing Progression to Overt Heart Failure

Once early structural or biomarker evidence of hypertensive heart disease is identified, management priorities shift toward preventing progression, alongside continued BP control.

Blood Pressure Control Targets

Guideline-concordant BP control remains the foundation of prevention at every stage, from Stage A risk through to established structural disease. For agent selection and target BP thresholds in patients with confirmed LVH or diastolic dysfunction, clinicians are referred to current ESC and ACC/AHA/HFSA guidance, which favour agents with evidence for regression of LVH alongside BP lowering.

Addressing Contributory Comorbidities

Diabetes, obesity, obstructive sleep apnoea, and chronic kidney disease each independently contribute to the hypertension-to-heart-failure trajectory and commonly coexist with hypertension. Systematic management of these comorbidities is an integral part of preventing progression, rather than a separate consideration.

Lifestyle Factors

• Sodium restriction and dietary pattern (e.g. DASH-style diet) to support BP control and reduce volume-related cardiac stress.

• Regular aerobic activity, which has evidence for improving diastolic function parameters independent of BP reduction.

• Weight management, given the additional haemodynamic and metabolic burden of obesity on the hypertensive heart.

Monitoring Cadence

• Newly diagnosed hypertension with additional risk factors: baseline echocardiography considered where LVH or structural disease is suspected clinically.

• Confirmed LVH or diastolic dysfunction: periodic echocardiographic reassessment, with interval guided by severity and overall risk profile.

• All hypertensive patients: structured home BP monitoring to track control and surface emerging trends between clinic visits.

• Where natriuretic peptides are elevated: closer clinical follow-up and consideration of specialist cardiology input.

6. Conclusion

Heart failure in hypertensive patients is, in the majority of cases, the endpoint of a years-long process that begins with sustained afterload and progresses through largely asymptomatic structural remodelling. This latency is precisely what makes early detection valuable: natriuretic peptide screening, echocardiographic assessment, and longitudinal home BP monitoring together provide the means to identify hypertensive heart disease well before symptomatic heart failure develops.

Key practice points for clinicians:

• Treat hypertension as a Stage A heart failure risk factor requiring proactive surveillance, not solely BP control in isolation.

• Consider natriuretic peptide testing and echocardiographic evaluation in hypertensive patients with additional risk factors or long-standing, historically poorly controlled disease.

• Recognise clinical red flags - reduced exercise tolerance, new oedema, unexplained weight gain - even in the absence of classic breathlessness.

• Use longitudinal home BP data to identify trends that may signal emerging cardiac involvement between clinic visits.

Encouraging hypertensive patients to conduct regular, structured home BP monitoring supports this surveillance model directly - providing the longitudinal dataset needed to detect the trends that precede overt heart failure, rather than relying on infrequent office readings that capture only a single moment in a years-long process.

Omron Healthcare offers a range of clinically validated home blood pressure monitors designed to support this approach, enabling healthcare professionals to integrate accurate, longitudinal BP data into the long-term surveillance of hypertensive patients. OMRON Academy has also created a free short course on hypertension and heart failure risk, available at academy.omron-healthcare.com.

Hypertension and atrial fibrillation frequently coexist, and each can accelerate the other's contribution to heart failure risk, making combined screening particularly valuable in this population. OMRON's Intellisense AFib technology, built into select home blood pressure monitors, allows AFib to be screened for automatically during routine BP measurement, offering hypertensive patients an additional layer of early detection alongside longitudinal BP tracking.

Approval code: OHEAPP-1202